Prospective Italian real-world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports.

Laura Pini,Giorgio Walter Canonica,Robert G Price,Aoife Maxwell,Peter Howarth,Stefania Colantuono,Diego Bagnasco,Cristiano Caruso

doi:10.1002/clt2.12067

Abstract

Prospective Italian real-world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports.

Highlights

To the Editor, Current asthma guidelines inform about evidence‐based approaches to optimize patient outcomes
Real‐life studies of the anti‐interleukin‐5 biologic, mepolizumab, are an important part of healthcare utilization evaluation and a number of real‐world experience (RWE) studies have been reported in severe eosinophilic asthma (SEA), including those from France, Australia and the ongoing global ‘REALITI‐A’ study, to which centres in Italy contributed.[3,4,5]
As Italy was a significant contributor to REALITI‐A and the Severe Asthma Network in Italy (SANI) has published retrospectively assessed data of RWE mepolizumab outcomes,[6] there is an opportunity to compare outcomes with mepolizumab in SEA as evaluated both prospectively and retrospectively in the same healthcare system

Summary

Introduction

To the Editor, Current asthma guidelines inform about evidence‐based approaches to optimize patient outcomes. As Italy was a significant contributor to REALITI‐A and the Severe Asthma Network in Italy (SANI) has published retrospectively assessed data of RWE mepolizumab outcomes,[6] there is an opportunity to compare outcomes with mepolizumab in SEA as evaluated both prospectively and retrospectively in the same healthcare system.

Results

Conclusion